Report Detail

Pharma & Healthcare Global Radioactive Diagnostic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM4574944
  • |
  • 20 February, 2024
  • |
  • Global
  • |
  • 109 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Radioactive Diagnostic Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Radioactive Diagnostic Drugs industry chain, the market status of Oncology (Single Photon Drugs, Positron Drugs), Cardiology (Single Photon Drugs, Positron Drugs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Radioactive Diagnostic Drugs.
Regionally, the report analyzes the Radioactive Diagnostic Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Radioactive Diagnostic Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Radioactive Diagnostic Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Radioactive Diagnostic Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Single Photon Drugs, Positron Drugs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Radioactive Diagnostic Drugs market.
Regional Analysis: The report involves examining the Radioactive Diagnostic Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Radioactive Diagnostic Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Radioactive Diagnostic Drugs:
Company Analysis: Report covers individual Radioactive Diagnostic Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Radioactive Diagnostic Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Cardiology).
Technology Analysis: Report covers specific technologies relevant to Radioactive Diagnostic Drugs. It assesses the current state, advancements, and potential future developments in Radioactive Diagnostic Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Radioactive Diagnostic Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Radioactive Diagnostic Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Single Photon Drugs
Positron Drugs
Blood Perfusion Drugs
Metabolizing Drugs
Receptor Binding Drugs
Others
Market segment by Application
Oncology
Cardiology
Neuroscience
Thyroid
Others
Market segment by players, this report covers
Curium
Medi-Radiopharma
Jubilant Radiopharma
Telix
Mallinckrodt
Cardinal Health
Bayer AG
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Group
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radioactive Diagnostic Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radioactive Diagnostic Drugs, with revenue, gross margin and global market share of Radioactive Diagnostic Drugs from 2019 to 2024.
Chapter 3, the Radioactive Diagnostic Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Radioactive Diagnostic Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radioactive Diagnostic Drugs.
Chapter 13, to describe Radioactive Diagnostic Drugs research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Radioactive Diagnostic Drugs
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Radioactive Diagnostic Drugs by Type
    • 1.3.1 Overview: Global Radioactive Diagnostic Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Radioactive Diagnostic Drugs Consumption Value Market Share by Type in 2023
    • 1.3.3 Single Photon Drugs
    • 1.3.4 Positron Drugs
    • 1.3.5 Blood Perfusion Drugs
    • 1.3.6 Metabolizing Drugs
    • 1.3.7 Receptor Binding Drugs
    • 1.3.8 Others
  • 1.4 Global Radioactive Diagnostic Drugs Market by Application
    • 1.4.1 Overview: Global Radioactive Diagnostic Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Oncology
    • 1.4.3 Cardiology
    • 1.4.4 Neuroscience
    • 1.4.5 Thyroid
    • 1.4.6 Others
  • 1.5 Global Radioactive Diagnostic Drugs Market Size & Forecast
  • 1.6 Global Radioactive Diagnostic Drugs Market Size and Forecast by Region
    • 1.6.1 Global Radioactive Diagnostic Drugs Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Radioactive Diagnostic Drugs Market Size by Region, (2019-2030)
    • 1.6.3 North America Radioactive Diagnostic Drugs Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Radioactive Diagnostic Drugs Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Radioactive Diagnostic Drugs Market Size and Prospect (2019-2030)
    • 1.6.6 South America Radioactive Diagnostic Drugs Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Radioactive Diagnostic Drugs Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Curium
    • 2.1.1 Curium Details
    • 2.1.2 Curium Major Business
    • 2.1.3 Curium Radioactive Diagnostic Drugs Product and Solutions
    • 2.1.4 Curium Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Curium Recent Developments and Future Plans
  • 2.2 Medi-Radiopharma
    • 2.2.1 Medi-Radiopharma Details
    • 2.2.2 Medi-Radiopharma Major Business
    • 2.2.3 Medi-Radiopharma Radioactive Diagnostic Drugs Product and Solutions
    • 2.2.4 Medi-Radiopharma Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Medi-Radiopharma Recent Developments and Future Plans
  • 2.3 Jubilant Radiopharma
    • 2.3.1 Jubilant Radiopharma Details
    • 2.3.2 Jubilant Radiopharma Major Business
    • 2.3.3 Jubilant Radiopharma Radioactive Diagnostic Drugs Product and Solutions
    • 2.3.4 Jubilant Radiopharma Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Jubilant Radiopharma Recent Developments and Future Plans
  • 2.4 Telix
    • 2.4.1 Telix Details
    • 2.4.2 Telix Major Business
    • 2.4.3 Telix Radioactive Diagnostic Drugs Product and Solutions
    • 2.4.4 Telix Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Telix Recent Developments and Future Plans
  • 2.5 Mallinckrodt
    • 2.5.1 Mallinckrodt Details
    • 2.5.2 Mallinckrodt Major Business
    • 2.5.3 Mallinckrodt Radioactive Diagnostic Drugs Product and Solutions
    • 2.5.4 Mallinckrodt Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Mallinckrodt Recent Developments and Future Plans
  • 2.6 Cardinal Health
    • 2.6.1 Cardinal Health Details
    • 2.6.2 Cardinal Health Major Business
    • 2.6.3 Cardinal Health Radioactive Diagnostic Drugs Product and Solutions
    • 2.6.4 Cardinal Health Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Cardinal Health Recent Developments and Future Plans
  • 2.7 Bayer AG
    • 2.7.1 Bayer AG Details
    • 2.7.2 Bayer AG Major Business
    • 2.7.3 Bayer AG Radioactive Diagnostic Drugs Product and Solutions
    • 2.7.4 Bayer AG Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Bayer AG Recent Developments and Future Plans
  • 2.8 GE Healthcare
    • 2.8.1 GE Healthcare Details
    • 2.8.2 GE Healthcare Major Business
    • 2.8.3 GE Healthcare Radioactive Diagnostic Drugs Product and Solutions
    • 2.8.4 GE Healthcare Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 GE Healthcare Recent Developments and Future Plans
  • 2.9 Mallinckrodt Pharmaceuticals
    • 2.9.1 Mallinckrodt Pharmaceuticals Details
    • 2.9.2 Mallinckrodt Pharmaceuticals Major Business
    • 2.9.3 Mallinckrodt Pharmaceuticals Radioactive Diagnostic Drugs Product and Solutions
    • 2.9.4 Mallinckrodt Pharmaceuticals Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Mallinckrodt Pharmaceuticals Recent Developments and Future Plans
  • 2.10 Bracco Group
    • 2.10.1 Bracco Group Details
    • 2.10.2 Bracco Group Major Business
    • 2.10.3 Bracco Group Radioactive Diagnostic Drugs Product and Solutions
    • 2.10.4 Bracco Group Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Bracco Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Radioactive Diagnostic Drugs Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Radioactive Diagnostic Drugs by Company Revenue
    • 3.2.2 Top 3 Radioactive Diagnostic Drugs Players Market Share in 2023
    • 3.2.3 Top 6 Radioactive Diagnostic Drugs Players Market Share in 2023
  • 3.3 Radioactive Diagnostic Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Radioactive Diagnostic Drugs Market: Region Footprint
    • 3.3.2 Radioactive Diagnostic Drugs Market: Company Product Type Footprint
    • 3.3.3 Radioactive Diagnostic Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Radioactive Diagnostic Drugs Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Radioactive Diagnostic Drugs Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Radioactive Diagnostic Drugs Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Radioactive Diagnostic Drugs Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Radioactive Diagnostic Drugs Consumption Value by Type (2019-2030)
  • 6.2 North America Radioactive Diagnostic Drugs Consumption Value by Application (2019-2030)
  • 6.3 North America Radioactive Diagnostic Drugs Market Size by Country
    • 6.3.1 North America Radioactive Diagnostic Drugs Consumption Value by Country (2019-2030)
    • 6.3.2 United States Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Radioactive Diagnostic Drugs Consumption Value by Type (2019-2030)
  • 7.2 Europe Radioactive Diagnostic Drugs Consumption Value by Application (2019-2030)
  • 7.3 Europe Radioactive Diagnostic Drugs Market Size by Country
    • 7.3.1 Europe Radioactive Diagnostic Drugs Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 7.3.3 France Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Radioactive Diagnostic Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Region (2019-2030)
    • 8.3.2 China Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 8.3.5 India Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Radioactive Diagnostic Drugs Consumption Value by Type (2019-2030)
  • 9.2 South America Radioactive Diagnostic Drugs Consumption Value by Application (2019-2030)
  • 9.3 South America Radioactive Diagnostic Drugs Market Size by Country
    • 9.3.1 South America Radioactive Diagnostic Drugs Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Radioactive Diagnostic Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Radioactive Diagnostic Drugs Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Radioactive Diagnostic Drugs Market Drivers
  • 11.2 Radioactive Diagnostic Drugs Market Restraints
  • 11.3 Radioactive Diagnostic Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Radioactive Diagnostic Drugs Industry Chain
  • 12.2 Radioactive Diagnostic Drugs Upstream Analysis
  • 12.3 Radioactive Diagnostic Drugs Midstream Analysis
  • 12.4 Radioactive Diagnostic Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Radioactive Diagnostic Drugs. Industry analysis & Market Report on Radioactive Diagnostic Drugs is a syndicated market report, published as Global Radioactive Diagnostic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Radioactive Diagnostic Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,665.68
    3,998.52
    5,331.36
    3,184.20
    4,776.30
    6,368.40
    519,355.20
    779,032.80
    1,038,710.40
    292,876.80
    439,315.20
    585,753.60
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report